An enrichment analysis identified a group of MM patients with an FK866-specific signature (FK866up and FK866dn, respectively) resembling drug-treated cells (FK866 treated-like) (Figure 3A and Table 2) among those with a higher expression of CD38 (top quartiles) that had a prognostic advantage over those with lower levels, in terms of overall survival (Figure 3B; p = 0.0023). The gene discussed is CD38; the disease is Miyoshi myopathy.